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Abstract: Prostate- specific antigen ( PSA) is a 33 KDa serine protease produced by both normal and  neoplastic   
prostate epithelial cells. The use of PSA as serum biomarker greatly increased the chance to detect prostate 
cancer at an early and still curable  stage . In our   study; we want to show that there is a correlation between: 
patients’ age ( > 50 years old); PSA levels; and the increased incidence of prostate cancer . For our study; we 
enrolled   253 patients; age 50 to 80 years old; serum PSA levels > 4ng/ml; and no lower urinary tract symptoms.  
From the 253 patients; 168 patients were age 60 to 80 years old ( lot  A) and  85 patients were age 50 to 60 years 
old ( lot B).  From lot A   24 patients (14;28%) had serum PSA levels > 4ng/ml and 18 of them ( 10;71%) were 
diagnosed  histologically with  adenocarcinoma of the prostate .  In lot B; 4 patients had serum PSA level> 
4ng/ml and only one was   diagnosed with  adenocarcinoma of the prostate. The incidence of prostate cancer was 
higher in lot A (10;7%) in comparison with patients 50 to 60 years old ( 1;17%).  The predictive value of PSA in 




Prostate cancer is one of the most frequent malignant diseases; especially in men of 
advanced age and its incidence has been continuously increasing. The advent of prostate-
specific antigen (PSA) has evolved in detection of prostate cancer ( PCa). It is well known that 
serum PSA levels are influenced by certain endogenous factors;  including : benign prostatic 
hyperplasia;  prostatitis and ischemia ; as well as exogenous factors ; such as : urethral 
instrumentation and digital rectal examination. Serum PSA occurs in multiple molecular  forms; 
including unbound free form and  complexed forms bound to α1- antichymotrypsin ( PSA-
ACT) ; α2-macroglobulin; protein C inhibitor; α1- antitrypsin  and inter-α- trypsin inhibitor. 
High serum PSA levels ( PSA > 10 ng/ml) have been associated with a diagnosis of prostate 
cancer. Lower   PSA values(4-10ng/ml) ; are associated with lower rates of positive prostatic 
biopsy. PSA testing is associated with an average lead time of 5-6 years for prostate cancer 
detection when a PSA level of 4;0 ng/ml is used as a threshold for biopsy.  
Lower PSA levels of 3;5-4;0 ng/ml for men 50-70 years old; and 2;0-2;5 ng/ml for men 
40-50 years old ; are generally considered abnormal. PSA levels increase with age ; in clinical 
practice a PSA level of 4 ng/ml in the blood  may be used ; often when there are two 
consecutive rises in PSA level ; as a threshold for further diagnostic studies ( e.g: prostatic 
biopsy). PSA levels of 4-10 ng/ml also occur in men with BPH; and prostate cancer is present 
in only 25% of patients with PSA levels in this range. To enhance the PSA performance; a 
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number of different strategies have been developed .These include use of PSA density; PSA 
velocity and the use of the molecular forms  of  PSA (free and bound). 
A) PSA  density : considers the relationship of the PSA level to the size of prostate. 
An elevated PSA might not arouse suspicion in a patient with a pre-existing enlarged prostate. 
B) PSA  velocity : is the change in PSA level over time. A steep rise in PSA level 
increases the likelihood of malignant prostate cancer. 
C )  Free versus bound PSA : Circulating PSA in the serum has been identified in two 
forms: free PSA  or  PSA bound to protein. The ratio of free to bound PSA decreases from 
benign to cancer. There is  more  free PSA in benign conditions whilst more bound PSA in 
cancer.  In addition to its use in early detection of prostate cancer; PSA has been used in 
predicting the extent of identified cancer; guiding the selection of further diagnostic studies; 
predicting the response to treatment or; early detection of recurrences.  
In our study we want to show that there is a correlation between: patients’ age (> 50 years 
old); PSA levels and the increased incidence of prostate cancer. 
 
MATERIALS AND METHODS 
 
Analyses were conducted on patients with PSA values greater   than 4 ng/ml. The 
population study measured 253 patients; divided in two subgroups; A and B; which enrolled 
168 and 85 patients with ages between 60-80 years (A group) and 50 to 60 years ( B group). 
All the recruited subjects did not accused lower urinary tract symptoms (LUTS). We 




To find out that the difference observed between the two groups are statistically 
significant a χ squared test follow by a Fisher exact test were performed and the conclusion 
was that indeed the differences are statistically significant as the p-value was p=0.011. 
Regarding the relative risk of the age in determining the occurrence of prostate cancer the 
value obtained was RR=7.589 with a 95% Confidence Interval: 1.019 to 56.520; which 
implies that the age over 60 represent a risk factor for prostate cancer. 
 

















24   patients from lot A (14; 28 %) had the PSA values > 4 ng/ml and in 18 of them (3;57 %) 
the biopsy result gave  the diagnostic of prostate cancer. From lot  B;  4 patients with PSA values > 
4 ng/ml had the biopsy result  of  prostate cancer. The incidence of prostate cancer is higher in 
patients from lot A (3;57 %) in comparison with patients 50 to 60 years old. The predictive value of 




In our study we have presented that ; patients higher than 60 years old; with the PSA 
values > 4 ng/ml present a higher incidence of the apparition of prostate cancer in comparison 
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